Catalyst Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

catalystbiosciences.com

Founded Year

2003

Stage

Merger | Merged

Total Raised

$111.93M

About Catalyst Biosciences

Catalyst Biosciences is developing next generation biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase therapeutics. Catalyst is focusing its product development efforts on drug candidates for hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation.

Catalyst Biosciences Headquarter Location

260 Littlefield Avenue

South San Francisco, California, 94080,

United States

650-871-0761

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Catalyst Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Catalyst Biosciences is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Catalyst Biosciences Patents

Catalyst Biosciences has filed 30 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Complement system
  • Coagulation system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/19/2021

3/8/2022

Coagulation system, Coagulopathies, EC 3.4.21, Blood tests, Hematology

Grant

Application Date

2/19/2021

Grant Date

3/8/2022

Title

Related Topics

Coagulation system, Coagulopathies, EC 3.4.21, Blood tests, Hematology

Status

Grant

Latest Catalyst Biosciences News

BGFV, TWOU and ASO among pre market losers

May 25, 2022

franckreporter/iStock via Getty Images Catalyst Biosciences ( CBIO ) -7%. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

  • When was Catalyst Biosciences founded?

    Catalyst Biosciences was founded in 2003.

  • Where is Catalyst Biosciences's headquarters?

    Catalyst Biosciences's headquarters is located at 260 Littlefield Avenue, South San Francisco.

  • What is Catalyst Biosciences's latest funding round?

    Catalyst Biosciences's latest funding round is Merger.

  • How much did Catalyst Biosciences raise?

    Catalyst Biosciences raised a total of $111.93M.

  • Who are the investors of Catalyst Biosciences?

    Investors of Catalyst Biosciences include Targacept, Sofinnova Ventures, Morgenthaler Ventures, Johnson & Johnson Innovation, EW Healthcare Partners and 8 more.

  • Who are Catalyst Biosciences's competitors?

    Competitors of Catalyst Biosciences include c-LEcta, LungLife AI, Bird Rock Bio, DNAtriX, NGM Biopharmaceuticals and 16 more.

You May Also Like

LungLife AI Logo
LungLife AI

LungLife AI is focused on the development of the LiquidBiopsy platform, a high-performance rare cell isolation technology for biomedical research and cancer diagnostics. LiquidBiopsy is a key enabling technology to realize the promise of personalized medicine, including the early detection of disease, real-time monitoring of patients, and the selection of individual therapeutic solutions.

DNAtriX Logo
DNAtriX

DNAtrix is developing modified viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells.

A
Acureon Pharmaceuticals

ACUREON Pharmaceuticals is a United States biopharmaceutical company primarily focused on specialty therapeutics to improve patient outcomes in the hospital areas of Infectious Diseases, Transplant, and ICU. To address the needs of the market, Acureon Pharma is focused on exploring opportunities that selectively acquire and enhance the market potential of commercially available therapeutics and late-stage development drugs. The company is located in the western suburbs of Philadelphia.

R
RevDia

RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.

N
NanoBioNexus

Founded in 2004, NanoBioNexus has grown to be a nanobiotechnology industry organization that showcases the latest nanotechnology research with a special interest in life sciences. Headquartered in San Diego, California and with offices in Tucson AZ, San Jose California and Vancouver WA, NanoBioNexus and its affiliate University Chapters aims to provide regular forums that present relevant nanotechnologies and discusses the impact and opportunities for industry professionals, academics, commercial companies and investors. Issues and challenges vital to this emerging field are also examined with scientific experts and industry pundits.

R
Recoly

Recoly N.V., a Netherlands Antilles based biotechnology company, is in the business of developing or acquiring platform technologies for use in the health care industry. Through the efforts of its research and development team, Recoly has developed a patented, platform technology which has been shown to prolong the half-life and improve the biological efficacy of protein and peptide pharmaceuticals by formulating them with PEGylated liposomes. The proteins and peptides bind non-covalently and yet with high affinity to the external surface of the liposomes; the proteins and peptides maintain their biological activity. No change in the protein/peptide manufacturing process is required. Recoly's business model is to partner with pharmaceutical and biotechnology companies to develop improvements of approved pharmaceutical products and thereby extend product franchises and enlarge product pipelines.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.